Ultrasound Stimulation of Pancreatic Beta Cells

超声刺激胰腺β细胞

基本信息

批准号：
8878256
负责人：
Vesna Zderic
金额：
$ 7.63万
依托单位：
GEORGE WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-01 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8878256
关键词：
Ablation Adipocytes Adrenal Glands Adverse effects Affect Amputation Atherosclerosis Beta Cell Blindness Blood Glucose Catecholamines Cattle Cell Membrane Permeability Cell physiology Cells Cessation of life Chromaffin Cells Chronic Clinical Trials Complex Coronary Arteriosclerosis Development Diabetes Mellitus Disease Dose Drug Formulations Effectiveness End stage renal failure Epidemic Epinephrine Failure Focused Ultrasound Gastrointestinal Hormones Glucose Goals Health Health Care Costs Hormones Human Human body Hyperglycemia Hyperlipidemia Hypertension Hypoglycemia Impairment Injection of therapeutic agent Insulin Insulin Resistance Kidney Diseases Lead Life Style Malignant Neoplasms Metabolic Metabolic Diseases Metformin Methods Modification Neuropathy Non-Insulin-Dependent Diabetes Mellitus Norepinephrine Obesity Operative Surgical Procedures Oral Pancreas Patients Peripheral Peripheral Vascular Diseases Pharmaceutical Preparations Prevalence Production Recommendation Reporting Retinal Diseases Risk Safety Smoking Stimulus Stroke Structure of beta Cell of islet Technology Testing Therapeutic Time Tissues Ultrasonic Therapy Ultrasonography United States Vision Weight Gain Work adiponectin analog blood glucose regulation cardiovascular risk factor combat design gastrointestinal glucagon-like peptide 1 hormone analog improved insulin secretion insulin sensitivity insulin sensitizing drugs interest novel novel strategies premature relating to nervous system release of sequestered calcium ion into cytoplasm research study response therapeutic target

项目摘要

DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is a complex metabolic disease that has reached epidemic proportions in the United States and around the world. The prevalence of diabetes in the United States is approximately 8.3%; worldwide, there are about 150 million cases, a number expected to double in the next 20 years. Diabetes increases the risk of development of chronic complications including atherosclerotic vascular diseases (coronary artery disease, stroke and peripheral vascular disease), retinopathy, nephropathy and neuropathies. These complications result in premature death, vision impairment and blindness, end stage kidney disease and amputation as well as engendering enormous health care costs. Type 2 diabetes results from the interplay of multiple metabolic abnormalities including decreased insulin sensitivity of peripheral tissues and insufficient insulin secretion from pancreatic b-cells. Clinical trials have shown that intensive blood glucose control together with reduction of the other cardiovascular risk factors can reduce the development of chronic complications. However, controlling type 2 diabetes is often difficult. Many patients are poorly compliant with lifestyle change recommendations, and pharmacological management routinely requires complex therapy with multiple medications, and loses its effectiveness over time. Thus, there is a growing interest in finding alternative methods for the treatment of diabetes. The objective of this proposal is to explore a novel, non- pharmacological approach that utilizes the application of ultrasound energy to augment insulin release from pancreatic b-cells. Low-intensity therapeutic ultrasound has been utilized before in production of reversible changes in cell membrane permeability, modulation of neural tissues, and enhancement of release of the adiponectin hormone from adipose cells, and epinephrine and norepinephrine from adrenal cells. Our experiments will focus on determination of effectiveness and safety of ultrasound application in stimulation of insulin release from the pancreatic b-cells. If shown successful our approach may eventually lead to new methods in the treatment of diabetes and other secretory diseases.

描述（由申请人提供）：2型糖尿病是一种复杂的代谢疾病，在美国和世界各地已经达到了流行比例。美国糖尿病的患病率约为8.3％；在全球范围内，大约有1.5亿个病例，预计未来20年将翻一番。糖尿病增加了慢性并发症发展的风险，包括动脉粥样硬化血管疾病（冠状动脉疾病，中风和周围血管疾病），视网膜病变，肾病和神经病。这些并发症导致过早死亡，视力障碍和失明，末期肾脏疾病和截肢以及增加巨大的医疗保健费用。 2型糖尿病是由多种代谢异常的相互作用导致的，包括降低外周组织胰岛素敏感性和胰腺B细胞的胰岛素分泌不足。临床试验表明，密集的血糖控制以及减少其他心血管危险因素可以减少慢性并发症的发展。但是，控制2型糖尿病通常很困难。许多患者符合生活方式改变建议，药理学管理通常需要使用多种药物进行复杂的治疗，并且随着时间的流逝而失去了有效性。因此，人们对寻找糖尿病治疗的替代方法越来越感兴趣。该提案的目的是探索一种新型的非药理方法，该方法利用超声能量的应用来增强胰腺B细胞释放胰岛素。在产生细胞膜通透性，神经组织的调节以及从脂肪细胞中脂联蛋白激素释放的释放，肾上腺素和去甲肾上腺素的脂肪蛋白激素释放的增强中，低强度的治疗超声已被利用。我们的实验将集中于确定超声应用在刺激胰岛B细胞释放胰岛素时的有效性和安全性。如果显示成功，我们的方法最终可能会导致治疗糖尿病和其他分泌疾病的新方法。